April 25, 2018
Migraine is one of the most prevalent neurological disorders worldwide, associated with substantial health, sociological, and economic consequences. The current…
April 6, 2018
What stands between patients and the treatment prescribed by their doctors? In some cases, the barriers are obvious. High co-pays…
February 18, 2018
Under Medicare’s 2007 Physician Quality Reporting Initiative (PQRI), eligible professionals who successfully report a designated set of quality measures on…
December 8, 2017
The Institute for Patient Access raised several concerns during ICER’s open input period. Based on the methodology described in the draft scoping document, however, it does not appear that ICER’s cost-effectiveness evaluation will adequately address these issues.
November 29, 2017
IfPA has concerns that ICER is undertaking the cost effectiveness evaluation of Erenumab before sufficient data exists. However, should the…
October 30, 2017
The Institute for Clinical and Economic Review recently evaluated treatments for tardive dyskinesia, a movement disorder related to the long-term use of antipsychotic medications to treat serious mental illness. Men and women with TD experience uncontrollable movements of their face, limbs or torso – along with intense social stigma.
ICER’s report says the treatments are not cost effective. But it leaves several key questions unanswered.
October 30, 2017
IfPA is concerned that ICER’s draft evidence report, dated October 2, 2017, undervalues the benefits that tardive dyskinesia (TD) patients…
August 1, 2017
Health benefits designs in both private and public health insurance programs include mechanisms to control the costs of care, resulting…
August 1, 2017
Non-medical switching occurs when health plans drive stable patients to switch from their current medication to a less expensive alternative.…
June 2, 2017
Abuse-deterrent formulations (ADF) of opioids resist crushing or dissolving for misuse, helping to curb widespread opioid abuse.
But a recent report from the Institute for Clinical and Economic Review underestimates ADFs’ value by ignoring several key benefits.
